An endogenous substance in brain, clonidine-displacing substance, binds to the same receptor populations as clonidine and is biologically active. Since receptor binding sites can be modeled by using specific antiligand antibodies, we tested the hypothesis that polyclonal antibodies raised in rat and rabbit against the clonidine analog p-aminoclonidine coupled to hemocyanin would recognize compounds structurally related to clonidine, including clonidine-displacing substance. Binding to anti-p-aminoclonidine antibodies was examined by using a competitive radioimmunoassay with tritiated p-aminoclonidine as the radioligand. Central vasodepressor agents that, like clonidine, are known to bind with high affinity to both imidazole sites and a 2 -adrenergic receptors in brain inhibited radioligand binding to anti-p-aminoclonidine antibodies. All of these agents contain imidazol(in)e and phenyl ring moieties as part of their chemical structures (e.g., oxymetazoline); a number of other compounds without one or both of these rings failed to cross-react with the antisera. Clonidine-displacing substance, partially purified from bovine brain, also inhibited specific radioligand binding to antf-p-aminoclonidine antibodies. The inhibition was dose dependent and high affinity (ICg,, 4 Units). The endogenous substance had no effect on the apparent affinity of the antibodies for the radioligand, but blocked a specific number of binding sites. Immunoprecipitation experiments showed that authentic clonidine-displacing substance, that which displaces tritiated p-aminoclonidine binding to membrane receptors, is recognized by anti-p-aminoclonidine antibodies. We conclude that a unique subset of structural determinants required for ligand interaction with both imidazole and a 2 -adrenergic receptors is critical for binding to anti-p-aminoclonidine antibodies, and that since clonidine-displacing substance is recognized by highly clonidine-specific antisera, it may also contain these determinants within its structure, namely the imidazol(in)e and phenyl ring systems. (Hypertension 1989;13:341-351)
C lonidine, a synthetic phenyl imidazolidine, is a highly potent antihypertensive agent that lowers arterial pressure largely by its action within the C, area of the rostral ventrolateral medulla oblongata (VLM). 1 -4 It has been widely assumed that the vasodepressor and other central actions of clonidine, such as sedation 5 - 6 and antiwithdrawal effects, 7 -8 occur as a result of its role as an a 2 -adrenergic receptor partial agonist. However, we have shown recently that clonidine binds with high H]PAC in the VLM, and to determine whether anti-PACs bind CDS from brain.
A preliminary report of related findings with a different antiserum has appeared. 27 
Materials and Methods

Production of Polyclonal Antisera
Immunogen was prepared as described previously. 27 The clonidine analogue PAC was coupled to hemocyanin (from Limulus polyphemus) with glutaraldehyde as the cross-linking agent. Sampling of combined media from exhaustive dialysis of the reaction product showed that nearly 40% of the [ 3 H]PAC (New England Nuclear, Boston, Massachusetts, 43 Ci/mmol) added as tracer was incorporated into the nondialyzable hemocyanin conjugate under the conditions used (i.e., coupling ratio, 0.4). The PACglutaraldehyde-hemocyanin conjugate (immunogen) was stored at -20° C until just before immunization.
At the time of injection, the immunogen was thawed and emulsified with an equal volume of complete Freund's adjuvant (1 mg immunogen/ml, final). The emulsion was injected into anesthetized rats (0.050 ml, i.p. and 0.075 ml, s.c.) and rabbits (1.0 ml, s.c). Booster injections were administered to rats at week 2, 3, and 4 and to rabbits at week 4 and 8. Ten days after the final injection, animals were anesthetized with halothane (2% in O 2 blown over the nose) and bled via cardiac puncture (rat) or femoral artery catheterization (rabbit). Blood samples were allowed to clot overnight at 4° C; the antisera were centrifuged at 300g and stored as 1 ml aliquots at -20° C.
Preparation of Immunoglobulin Fractions From Antisera
For most experiments, a total protein fraction was precipitated from rat (anti-PAC i) and rabbit (anti-PAC^ antisera with 50% (wt/vol) ammonium sulfate. 27 Precipitates were reconstituted in a minimum amount of 0.9% saline, dialyzed, adjusted to serum-equivalent volumes, and then stored frozen at -20° C until radioimmunoassay.
Alternatively, anti-PAC 2 immunoglobulin Gs were affinity purified from serum by Protein A Sepharose chromatography. Anti-PAC 2 serum (12 ml) was loaded onto a Protein A Sepharose (Pharmacia Biotechnology Prods., Piscataway, New Jersey) column (10x0.9 cm, i.d.) that had been equilibrated at 4° C with phosphate-buffered saline (pH 7.0). The column was washed with phosphate-buffered saline at a flow rate of approximately 20 ml/hr until the optical density at 280 nm (OD280) of the effluent was less than 0.1. Immunoglobulin Gs were eluted in a 0.1 M glycine buffer, pH 3.0, and fractions of 1 ml were collected and immediately neutralized with 0.1 M Tris base. Elution fractions containing greater than 0.1 OD280 were pooled and the immunoglobulin Gs concentrated by precipitating with 50% ammonium sulfate. Saline-dialyzed aliquots of the anti-PAC 2 immunoglobulin Gs were stored as 3x concentrates (relative to original serum immunoglobulin G content) at -20° C.
Tritiated p-Aminoclonidine Radioimmunoassay
To examine the binding properties of anti-PAC polyclonal antibodies, a radioimmunoassay with unconjugated [ 3 H]PAC as radioligand was adapted as described 27 from the method of Sangameswaran and deBlas. 28 Briefly, an aliquot of ammonium sulfate-precipitated anti-PAC immunoglobulins was thawed, then diluted to a 10x stock solution with bovine serum albumin (1 mg/ml). The anti-PAC stock was added to 50 mM Tris-HCl (pH 7.4) containing the compound to be tested or CDS (see below) to give the final dilution indicated and was preincubated at 25° C for 15 minutes. To define nonspecific binding, unlabeled PAC (20 ^.M) was included in parallel preincubations. [ 3 H]PAC (1 nM, or as specified) was added to all samples (incubation volume, 0.5 ml) that were then vortexed and incubated for 15 minutes at 25° C, followed by 1 hour on ice. The reaction was terminated by precipitating with carrier bovine gamma globulin (0.125% wt/vol) and ice-cold polyethylene glycol 8000 (7.5% wt/vol, final volume, 1.0 ml). Samples were vacuum-filtered over Whatman GF/B filters using a modified cell harvester (Brandel, Gaithersburg, Maryland). The filters were washed with 6-8 ml of 8% polyethylene glycol in Tris-HCl, pH 7.4, then transferred to scintillation minivials, covered with 5 ml of scintillation cocktail, and counted at 45-50% efficiency.
Protein was measured by the Coomassie Blue dye binding method of Bradford, 29 as modified by Read and Northcote, 30 with bovine gamma globulin as standard.
Isolation of Clonidine-Displacing Substance
Extracts of calf brain containing CDS were prepared according to methods described elsewhere, 14 -1627 with slight modification. Fresh brains, obtained from a local slaughterhouse (maximum 2 hours postmortem), were cleaned of major blood vessels and membranes, and the cerebellum was removed. The tissue was chopped into small pieces, then homogenized in three volumes (vol/wt) of boiling distilled water using a Polytron (Brinkman Instruments, Westbury, New York). The homogenate was centrifuged at 100,000g for 30 minutes at 4° C. The supernatant then was denatured in a microwave oven by heating just to boiling and recentrifuged for 15 minutes; the resulting supernatant was freeze-dried overnight. The solids were reconstituted in distilled water (50-100 ml/2 brain equivalents) and were transferred to a dialysis bag made of H45 membrane tubing (Thomas Scientific, Philadelphia, Pennsylvania) with a cutoff of 3,500 MW. Dialysis was carried out overnight at 4° C against 3x20 volumes (vol/vol) of distilled water. The dialysis media (diffusates) were combined and freeze-dried. The low molecular weight solids were extracted with 20 volumes (vol/wt) of high-purity methanol by bath sonicating for 3 minutes at room temperature. The extract was decanted and the residue re-extracted with 5-10 volumes of fresh methanol. The extracts were pooled, filtered over Whatman (Clifton, New Jersey) No. 1 paper, and then aliquoted and dried in a Speed-Vac (Savant Instruments, Farmingdale, New York). CDScontaining aliquots were stored dry at -70° C until immediately before use when they were reconstituted in distilled water. 14 
Data Analysis
Competition curves from studies of radioligand binding to antibody recognition sites were analyzed by linear regression of Hill plots. More complex data and data from multiple experiments were analyzed with programs originally designed for quantification of membrane receptor-ligand interactions: the Equilibrium Binding Data Analysis (EBDA) 
Results
Binding of Tritiated p-Aminoclonidine to Anti-p-Aminoclonidine Immunoglobulins
To determine whether antibodies to PAC were produced in rat or rabbit after immunization with the synthetic PAC-glutaraldehyde-hemocyanin conjugate, the specific binding of unconjugated [ Table 1 .
For the range of radioligand concentrations examined, rat anti-PACi appeared to contain at least two classes of antibody binding sites for [ sites in anti-PAC,. The goodness of fit of this data was not improved using a two-site model (F=1.22, p>0.30). The titer (calculated as the total number of antibody binding sites [B^]) was significantly greater for rabbit anti-PAC 2 compared with the rat antiserum. Affinity-purified (Protein A Sepharose chromatography) antisera had binding characteristics similar to those for the ammonium sulfateprecipitated preparations.
Thus, polyclonal antisera were produced in both rat and rabbit, which recognized, with high affinity, the PAC epitope of the protein-conjugated antigen. The rabbit antiserum, however, showed a considerably higher titer of anti-PAC than the antiserum raised in rat and appeared to contain a single class of specific antibodies.
Specificity-of Binding to Anti-p-Aminoclonidine Antisera
Anti-PAC antisera were examined for specificity of binding by measuring the cross-reactivity of PAC, clonidine, and a series of other compounds that are either chemically or functionally related to clonidine or are known to interact with imidazole sites or a 2 -adrenergic receptors, or both.
•- 91216 Crossreactivity was measured as inhibition in a competitive radioimmunoassay with [ *Values (mean±SEM) are the result of combined analysis of data from four rat anti-p-aminoclonidine (anti-PAC,) and three rabbit (anti-PACJ experiments using the nonlinear curve-fitting program (LIGAND) of Munson and Rodbard. 32 Six concentrations of tritiated PAC, ranging from 0.2 to 56 nM were incubated in triplicate with the ammonium sulfate-precipitated immunoglobulin fraction of each antiserum, at a 1:500 dilution of anti-PAC, (16 /ig total protein) and a 1:10,000 dilution of anti-PAC 2 (1 n% total), as outlined in Materials and Methods. Nonspecific binding was determined using 20 jtM unlabeled PAC. Figure 6 for structure), oxymetazoline (2-[4-terf-butyl-2,6-dimethyl-3-hydroxybenzyl]-2-imidazoline), and tolazoline (2-benzyl-2-imidazoline) all inhibited binding to anti-PAC,. The displacement curves for these agents were shifted still further to the right relative to PAC and clonidine, indicating that much higher concentrations were required for inhibition.
The binding affinities (IC50) of these and several other clonidine-related imidazole compounds at anti-PAC, and at anti-PAC 2 recognition sites are given in Table 2 . PAC and clonidine were nearly equipotent (2-5 nM) in cross-reacting with both antisera; chloroethylclonidine was approximately 10-fold less potent. Up to lO^x the IC50 for clonidine was required to give 50% inhibition at anti-PAC, or anti-PAC 2 sites with the cross-reactants oxymetazoline, naphazoline, and tolazoline. The arylalkyl
, and MPV 830 (4(5)-[a-hydroxy-2,6-dimethylbenzyl]imidazole) were weakly crossreactive with anti-PAC, and noncross-reactive with the anti-PAC 2 antiserum. In general, the order of potency of binding of these compounds was similar for the rat and rabbit antisera. However, anti-PAC 2 appeared more specific for clonidine.
Pseudo-Hill coefficients for all of the compounds, except naphazoline, were near unity. This suggests that, at the high affinity recognition sites labeled by 1 nM [ for example, with anti-PAC,.) Naphazoline appeared to discriminate among more than one class of sites with high affinity for the radioligand in both antisera. Thus, the multiple species of anti-PAC antibodies undoubtedly present in the two antisera exhibit indistinguishable, apparently single-class affinities for all of the cross-reacting ligands (except naphazoline) under the radioimmunoassay conditions specified.
FIGURE 2. Inhibition of tritiated p-aminoclonidine (['HIPAC) binding to rat (anti-PAC,) immunoglobulins by clonidine-related compounds. The immunoglobulincontaining fraction of anti-PAC) (1 -500) waspreincubated with the compounds indicated at a series of concentrations in Tris-
Other compounds that did not effectively crossreact (i.e., inhibit 50% of specific [ Table 3 . A number of naturally occurring and synthetic substances had no significant effect on binding. These included the neurotransmitters acetylcholine, GABA, norepinephrine, and serotonin. Some compounds, most of which were imidazoles [e.g., idazoxan ([l,4-benzodioxan-2-yl]-2-imidazoline); see Figure 6 for structure], histamine, histidyl-tyrosine, cimetidine (N-Cyano-N-me\hy\-N not shown) , that is, it had no effect in this assay system.
Thus, binding to polyclonal anti-PAC antibodies raised in two different species was highly specific. Only those agents that, like clonidine, contain phenyl and imidazol(in)e ring moieties in their structures competed for binding to antibody recognition sites.
Recognition of Clonidine-Displacing Substance by Anti-p-Aminoclonidine Antibodies
Given the strict structural requirements for crossreactivity, we sought to determine whether CDS was truly clonidine-like in that it also was recognized by anti-PAC antibodies. As shown in Figure  3 , increasing amounts of bovine brain extract containing CDS inhibited [ To further characterize the apparent crossreactivity of CDS with anti-PAC antibodies, anti-PAC 2 immunoglobulin G that had been affinity purified on Protein A Sepharose (see Materials and Methods) was used. The immunoglobulin G was preincubated either in the presence or absence of a fixed amount of CDS (approximating its ICJO at anti-PAC, sites: average, 3.2 Units), and then saturation binding of [ (Figure 4) showed that CDS had no effect on the radioligand binding affinity of anti-PAC 2 : the slopes for data obtained in either condition were parallel, giving nearly identical K 6 values. However, a significant number of [ 3 H]PAC binding sites were blocked by CDS as indicated by the shift in Scatchard x intercept (B^ in the presence of CDS. The results are typical of a noncompetitive interaction and are expected for antibody binding, which is an essentially irreversible process, that is, primarily association and not dissociation dependent. 33 Nonspecific binding was unaffected by coincubation with CDS.
Since the experiments described here involved the use of partially purified extracts of brain containing CDS and since CDS is defined in all of our studies i*-i6,27 ^ a substance that displaces the binding of [ the displacing substance found in brain extract was in fact responsible for the inhibition of binding to anti-PAC antibodies. To do this, aliquots of a reconstituted CDS-containing extract were pretreated with logarithmically increasing amounts of affinitypurified anti-PAC 2 immunoglobulin G, then total immunoglobulin G was immunoprecipitated using Staphylococcus aureus cells (Pansorbin; Calbiochem, San Diego, California). The supernatants were assayed for remaining CDS by displacement of [ 3 H]PAC in the standard radioreceptor assay with bovine frontal cortex membranes ( Figure 5 ). Incubation with increasing amounts of immunoglobulin G resulted in a decrease in the amount of CDS measured in the supernatant. At a 1:100 dilution of anti-PAC 2 , 83% of the displacing activity present (1.3±0.2 Units; n=l) was removed from the medium. In contrast, incubation of CDS with equivalent dilutions (determined spectrophotometrically by ODjgo) of nonspecific affinity-purified total rabbit immunoglobulin G (Sigma Chemical Co.) had no effect.
In a separate series of experiments, anti-PAC 2 immunoglobulin G was used to detect paraformaldehyde-fixed CDS from different preparations. Extracts of whole bovine brain, bovine VLM, and whole rat brain were serially diluted, blotted (3.0-0.006 Units) onto filter paper, and processed. 34 The immunoblots clearly indicated positive staining with anti-PAC 2 , which was detectable to approximately 0.06 Units (data not shown). Nonspecific staining in the absence of primary immunoglobulin G was near background. The presence of CDS in rat brain as well as bovine brain was thus confirmed. 13 This is critical since a number of the biological actions described for partially purified CDS have been in ra t i4,i8,2o j n addition, bovine VLM, presumably containing the rostral clonidine-sensitive zone, showed strong, concentration-dependent staining with anti-PAC 2 immunoglobulin G.
Discussion
Polyclonal antisera were produced against a PACglutaraldehyde-hemocyanin conjugate in rat and rabbit. The antisera exhibit different anti-PAC titers, yet have comparably high affinities for free [ 3 H]PAC as measured by radioimmunoassay. These affinities are nearly identical to that of an antiserum raised against a derivative of 4-hydroxyclonidine for tritiated clonidine (0.58 nM). 35 Binding to anti-PAC antibody recognition sites is highly specific. In addition to PAC itself, anti-PAC binds clonidine and chloroethylclonidine with high affinity. The phenyl-imidazolines naphazoline, oxymetazoline, and tolazoline, and the imidazoles detomidine, medetomidine, and MPV 830 bind with intermediate and low affinities, respectively. Several other imidazole-containing compounds also weakly interact with the antisera. In general, of the synthetic and naturally occurring compounds tested, only those with a substituted phenyl group linked via a single-atom spacer to an imidazol(in)e ring crossreact with anti-PAC.
In the present study, we have demonstrated that endogenous CDS 13 in brain is recognized by anti-PAC antisera. As with the other cross-reactants, CDS (bovine brain extract) inhibits [ 
Recognition by Anti-p-Aminoclonidine Antibodies: Structure-Activity Relations
The results presented here indicate that, as with other polyclonal and monoclonal antibodies, certain structural requirements must be fulfilled for an agent to exhibit cross-reactivity with anti-PAC antibodies. The necessary structural elements are, not unexpectedly, derived from PAC or, more specifically, the clonidine portion of the immunogen. Clonidine (2-[2,6-dichloroanilino]-2-imidazoline; Figure 6 ) contains a partially saturated imidazole (imidazoline) ring covalently bound through a nitrogen atom to a substituted phenyl ring, with the exocyclic (imidazolidine) tautomer as the predominant form (see Figure 6 ). 1 The drug is protonated (85%) at neutral pH due to its net positive charge and, as a result, in solution the two ring systems are aplanar and nonperpendicular. 36 - 37 The distance between the one nitrogen of the imidazoline ring and the center of the aromatic ring has been reported as 5 A. 38 The p-amino group of PAC that, presumably, 
FIGURE 3. Inhibition of tritiated p-aminoclonidine (1 3 H]PAC) binding to rat (anti-PACi) immunoglobulins by clonidine-displacing substance (CDS) and PAC. Increasing amounts of partially purified CDS (up to 8 Units) or PAC were preincubated in triplicate with anti-PACi immunoglobulins, then assayed as described for cross-reactive drugs. Values represent the mean±SEM for three experiments.
serves as the point of attachment of the hapten to the carrier appears to play little or no role in ligand recognition. In fact, chloroethylclonidine contains a bulky (Af-/3-chloroethyl-N-methyl)-methylamino substituent at the para position, yet still binds with high affinity to anti-PAC antibodies.
Based on our ligand specificity studies, the following structural elements of clonidine appear to be imprinted within the antibody recognition site. (1) Both ring structures are necessary. Compounds possessing only an imidazole ring (e.g., histamine, cimetidine) or phenyl ring (epinephrine, norepinephrine) do not cross-react with anti-PAC. (2) Replacing the ring-linking nitrogen of clonidine with a carbon atom and changing or removing the phenyl ring substituents (see Figure 6 , naphazoline; also oxymetazoline, tolazoline) causes a decrease in affinity, but does not abolish binding. These tetrahedral benzyl-imidazolines are moderately crossreactive. (3) Connecting a substituted phenyl ring via a carbon spacer to an unsaturated imidazole ring at the carbon four (five) position (detomidine, see Figure 6 ; medetomidine and MPV 830) allows only low affinity binding. (4) Attachment of the imidazole ring at the position one nitrogen, as in 1-benzylimidazole, results in a complete loss of binding to anti-PAC. (5) The ring-to-ring distance or a tolerance in the flexibility of conformation of the ring systems, appears critical for interaction at anti-PAC recognition sites. Benzimidazole (collapsed ring distance: no spacer), idazoxan (dioxan structure, see Figure 6 ), MPV 295 and phentol- amine (extended ring distances: two-atom spacers), and histidyl-tyrosine (seven-atom spacers) fail to cross-react effectively and exhibit only a weak interaction with anti-PAC antibodies. Thus, in general, the spatial orientation of the phenyl and imidazol(in)e rings, and perhaps their degree of substitution, constitute the critical chemical determinants of the clonidine epitope. Since they are not readily available for study, it is unclear whether unsaturated (imidazole) analogues of the partially saturated imidazolines, linked at ring position two (i.e., substituted 2-benzylimidazoles), would be as effective as clonidine in binding to anti-PAC antibodies.
H]PAC) to rabbit (anti-PAC2) antibodies in the presence and absence ofclonidinedisplacing substance (CDS). Affinity-purified anti-PACj immunoglobulin G (IgG) was preincubated at a 1 '• 10,000 final dilution with and without CDS (3.2 units of methanolextracted CDS per tube
Recognition by Anti-p-Aminoclonidine Antibodies: Antihypertensive Agents and Their Receptors
Two types of receptors are localized in the VLM that are labeled by the clonidine derivative [ 3 H]PAC. It is at 'er 2 -adrenergic receptors in the C, area of this region that clonidine has traditionally been thought to act as a partial agonist to lower arterial pressure. 1 -39 However, clonidine binds with even higher affinity to a newly discovered class of putative imidazole receptors in VLM, which are distinct from adrenergic and histaminergic receptors. 9 Recent evidence from our laboratory suggests that the vasodepressor potency of clonidine and related compounds correlates best with binding affinity at imidazole receptor sites, not a 2 -adrenergic receptors. 12 Alternatively, vasodepressor potency may result from concerted effects via both receptor types. This dual action would be structurally represented by the phenyl moiety of phenylethylamine adrenergic agents along with the imidazol(in)e moiety of histaminergic agents, both of which are present in clonidine-like agents. These possibilities raise the question as to whether the recognition sites of clonidine-specific antibodies resemble classic a 2 -adrenergic sites, imidazole sites, or a hybrid of both receptors.
Specific anti-PAC antibodies cross-react with clonidine and only a few other agents, all of which bind 40 Naphazoline and oxymetazoline also lower arterial pressure on central administration, 41 but only at doses that exceed those of clonidine by two orders of magnitude. These two compounds also exhibit a substantially lower affinity for anti-PAC sites compared with clonidine. In addition, detomidine, medetomidine, and MPV 830 are potent sedatives that act as vasodepressor agents via central mechanisms. 42 -43 These sedative agents are a 2 -selective (P. Ernsberger, unpublished observation) and only weakly cross-reactive with anti-PAC antibodies. Thus, binding to anti-PAC antibodies defines a unique subset of agents with affinities for anti-PAC sites that appear to be qualitatively related to their effectiveness in lowering arterial pressure within the central nervous system. Although several noncrossreactive compounds show moderate central hypotensive actions, such as guanabenz (a 2 -adrenergic), and idazoxan and cimetidine (imidazole), 12 binding to anti-PAC antibodies may be useful in providing information for the design of novel centrally acting antihypertensive agents.
Recognition by Anti-p-Aminoclonidine Antibodies: Clonidine-Displacing Substance
The recognition of CDS by antibodies raised against the clonidine analog PAC is added evidence that this endogenous substance from brain is truly clonidine-like. The fact that anti-PAC antibodies exhibit such strict structural requirements for binding, and yet. CDS is also recognized by these antibodies, strongly suggests that the natural substance shares some of the same chemical elements as clonidine and the other cross-reactants, namely, the phenyl and imidazol(in)e ring moieties. The reported finding that CDS is relatively hydrophobic and positively charged at neutral pH 13 is consistent with the presence of these structural elements. This observation may provide useful clues for the structural analysis and identification of purified CDS.
Binding to clonidine-specific antibodies also supports our proposal that CDS is a unique substance in brain. 16 CDS appears to be distinct from a number of endogenous compounds, including the catecholamines and other neurotransmitters such as acetylcholine, GABA, histamine, and serotonin, since these do not bind effectively to anti-PAC. Furthermore, CDS is one of a small and unique set of agents that bind to the imidazole and a 2 -adrenergic receptor populations in VLM 1516 as well as to anti-PAC antibodies. This finding may account for the clonidine-related central cardiovascular actions of CDS. 1417 We cannot, of course, rule out the possibility that more than one substance in our partially purified CDS preparation combines in the antibody recognition site to result in a unique profile of inhibition of [ 3 H]PAC binding. However, the dose-response relation for clonidine and for CDS appear to be similar, based on pseudo-Hill coefficients. In addition, receptor binding experiments using the same CDS preparation described here indicate that these extracts contain a single active species. 16 Furthermore, our data show that more than 85% of this inhibitory species can be immunoprecipitated with anti-PAC antibodies.
